Content Type: Commentary & Opinion

The Pharmaceutical Industry’s Quiet Win in the One Big Beautiful Bill Act

March 6, 2026

Combination-Only Approvals as a Barrier to Affordable HIV Care

March 6, 2026

The Strength and Importance of Government-Funded Patents for Approved Drugs (Reply)

March 6, 2026

Generic Liraglutide—Overlooked but Not Forgotten

March 6, 2026

The 25th Anniversary of a Nearly Unknown Health Policy Turning Point

March 6, 2026

Serial Patent Litigation: an Emerging Strategy to Delay Entry of Generic Competition

March 6, 2026

Op-Ed: Corporate Support Cannot Make Up for Threats to the NIH Budget

March 6, 2026

Flaws in the FDA’s New Priority Voucher Program

March 6, 2026

Biosimilar Interchangeability and Substitution in the US: What Comes Next?

March 6, 2026

Halting Hyaluronidase Hopping to Maintain the Integrity of Medicare Drug Price Negotiation

March 6, 2026

Enhancing Formulary Accessibility: a Step Toward Better Care

March 6, 2026

Mapping Intellectual Property Abuses in the Pharmaceutical Field

March 6, 2026